Exchange Traded Concepts LLC Grows Stock Position in Gilead Sciences, Inc. $GILD

Exchange Traded Concepts LLC increased its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 45.7% in the 4th quarter, HoldingsChannel reports. The firm owned 243,532 shares of the biopharmaceutical company’s stock after purchasing an additional 76,432 shares during the period. Exchange Traded Concepts LLC’s holdings in Gilead Sciences were worth $29,891,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the stock. Norges Bank purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at about $2,150,268,000. Ameriprise Financial Inc. increased its stake in shares of Gilead Sciences by 397.6% during the second quarter. Ameriprise Financial Inc. now owns 6,748,403 shares of the biopharmaceutical company’s stock worth $748,147,000 after buying an additional 5,392,191 shares during the period. Invesco Ltd. raised its holdings in Gilead Sciences by 33.5% in the second quarter. Invesco Ltd. now owns 13,521,228 shares of the biopharmaceutical company’s stock valued at $1,499,098,000 after acquiring an additional 3,394,330 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Gilead Sciences by 164.4% in the third quarter. Assenagon Asset Management S.A. now owns 3,489,062 shares of the biopharmaceutical company’s stock valued at $387,286,000 after acquiring an additional 2,169,266 shares in the last quarter. Finally, First Trust Advisors LP lifted its stake in Gilead Sciences by 154.3% in the third quarter. First Trust Advisors LP now owns 3,089,283 shares of the biopharmaceutical company’s stock worth $342,910,000 after acquiring an additional 1,874,508 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on GILD. Citigroup reissued a “buy” rating on shares of Gilead Sciences in a research report on Friday, March 6th. Needham & Company LLC reaffirmed a “buy” rating and set a $170.00 price objective on shares of Gilead Sciences in a research report on Monday, February 23rd. Truist Financial boosted their target price on shares of Gilead Sciences from $145.00 to $152.00 and gave the stock a “buy” rating in a research note on Wednesday, February 11th. Royal Bank Of Canada increased their target price on Gilead Sciences from $103.00 to $118.00 and gave the company a “sector perform” rating in a report on Wednesday, February 11th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Twenty-four analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $157.62.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Gilead agreed to buy Ouro Medicines for up to about $2.18B to expand its inflammation/immunology franchise, strengthening longer‑term growth optionality beyond established HIV and antiviral products. Gilead to Acquire Ouro Medicines in $2.18B Deal, Expand Inflammation Pipeline
• Positive Sentiment: Gilead has been adding immunology and CAR‑T assets to diversify its pipeline and bolster oncology exposure — a strategic shift that could lift medium/long‑term revenue growth if integration and clinical readouts succeed. Can Gilead’s Recent Acquisitions Strengthen Its Long-Term Growth Outlook?
• Positive Sentiment: Gilead recently reported an earningsbeat and set FY‑2026 EPS guidance in the $8.45–$8.85 range, signaling stable profitability and management confidence; consensus still trails that guidance, which supports valuation. Gilead Sciences Trading / Company Report
• Positive Sentiment: Erste Group nudged up its FY‑2026 EPS forecast for Gilead, a modest analyst raise that reinforces hopes for better-than-consensus earnings next year.
• Neutral Sentiment: Analyst consensus (average brokerage recommendation) sits at a Buy — helpful context but potentially already reflected in the share price; take analyst ratings as background, not a catalyst. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Neutral Sentiment: Zacks highlights Gilead as a value‑oriented pick under its style scores, which may attract income/value investors but is not an immediate price driver. Here’s Why Gilead Sciences (GILD) is a Strong Value Stock
• Neutral Sentiment: Industry event notices (e.g., SK pharmteco symposium) are peripheral to Gilead’s near‑term stock movement and unlikely to be material. SK pharmteco to Host Innovations in Pharmaceutical Manufacturing Symposium
• Negative Sentiment: Market skepticism: analyst optimism and “Buy” consensus could be priced in, and investors may be trimming positions after recent gains (Gilead has traded near a 52‑week high in the past year), leading to downward pressure. Is Gilead (GILD) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Deal risk and near‑term cost: the ~ $2.2B acquisition and other purchases increase upfront cash outlays and execution risk (integration, trial outcomes), which can weigh on the stock until benefits are demonstrated.
• Negative Sentiment: Technical/flow factors: trading volume is below the stock’s average and the price is below the 50‑day moving average, consistent with the current down move and limited buying momentum.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the completion of the sale, the director directly owned 8,920 shares of the company’s stock, valued at $1,101,620. This trade represents a 35.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Daniel Patrick O’day sold 10,000 shares of the business’s stock in a transaction on Friday, February 27th. The shares were sold at an average price of $144.79, for a total transaction of $1,447,900.00. Following the completion of the transaction, the chief executive officer directly owned 642,308 shares in the company, valued at $92,999,775.32. This represents a 1.53% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 309,280 shares of company stock valued at $44,068,850 over the last ninety days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Price Performance

Shares of NASDAQ:GILD opened at $134.25 on Friday. Gilead Sciences, Inc. has a 12 month low of $93.37 and a 12 month high of $157.29. The firm has a market capitalization of $166.63 billion, a P/E ratio of 19.83, a P/E/G ratio of 1.79 and a beta of 0.37. The company has a debt-to-equity ratio of 0.98, a current ratio of 1.55 and a quick ratio of 1.40. The company’s fifty day moving average price is $144.09 and its 200 day moving average price is $128.57.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, topping analysts’ consensus estimates of $1.83 by $0.03. The business had revenue of $7.93 billion for the quarter, compared to analysts’ expectations of $7.68 billion. Gilead Sciences had a return on equity of 49.46% and a net margin of 28.90%.The business’s revenue was up 4.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.90 earnings per share. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, sell-side analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 30th. Shareholders of record on Friday, March 13th will be paid a $0.82 dividend. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. This represents a $3.28 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date is Friday, March 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.45%.

Gilead Sciences Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.